APP and Alzheimer disease: Early-onset APP gene-mutated patient cells were used to produce a model of iPSCs overexpression, including a double mutation (KM670/671NL) of APP, which increases the total Aβ burden [36], followed by APP duplication to prepare iPSCs from patients with late-AD onset.